IVD · Inflammation / Clinical Markers

Human Pancreatic Elastase Rapid Test

A rapid qualitative screening test for pancreatic elastase-1 (PE-1) in human fecal specimens, supporting assessment of exocrine pancreatic insufficiency risk. Results are read at 10 minutes for professional laboratory, clinic and screening settings.

Method

Colloidal gold sandwich immunochromatography

Specimen

Human feces

Result time

10 minutes

Storage

2-30°C

Contact Sales
Human Pancreatic Elastase Rapid Test
Product Features

Product Features

1

Focused biomarker

Built around Human fecal pancreatic elastase-1 (PE-1) with specimen and workflow details aligned to practical screening use.

2

Rapid workflow

Readable within 10 minutes under the standard procedure for efficient professional testing.

3

Clear specifications

Method, specimen, package, storage and quality-control points are organized for easy customer review.

4

OEM/ODM ready

Label language, packaging, IFU documents and registration-support files can be discussed by project.

Technical Specifications

Technical Specifications

Visual screening cutoff about 200 μg/g; draft analytical detection capability about 50 μg/g

Product nameHuman Pancreatic Elastase Rapid Test
TargetHuman fecal pancreatic elastase-1 (PE-1)
MethodColloidal gold sandwich immunochromatography
SpecimenHuman feces
Reading time10 minutes
Package1 / 5 / 10 / 20 tests per kit
Storage2-30°C
InterpretationVisual screening cutoff about 200 μg/g; draft analytical detection capability about 50 μg/g
Quality controlInternal control line/area, positive and negative material checks, lot release and retained-sample traceability.
Intended use noteFor professional in vitro diagnostic use. Final registered intended use and performance data follow the package insert and local requirements.
Product Gallery

Product Gallery

Human Pancreatic Elastase Rapid Test
Human Pancreatic Elastase Rapid Test
Human Pancreatic Elastase Rapid Test
For professional use. Product images and specifications are for website presentation; final labels, IFU and registration claims follow controlled documents and local regulatory requirements.